NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05247268 2025-04-06
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
Phase 2 Recruiting
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT05675787 2024-07-11
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Peking University People's Hospital
Phase 2 Recruiting
NCT00577122 2023-10-16
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Indiana University
Phase 2 Completed
NCT03567655 2018-06-26
Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer
Asan Medical Center
Phase 2 Unknown
NCT00064025 2016-04-11
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
GOG Foundation
Phase 2 Completed
NCT00739830 2015-07-01
Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00033358 2013-05-03
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
National Cancer Institute (NCI)
Phase 2 Completed